◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW MEDIUM

Masteron

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW MEDIUM

"Cosmetic-AAS archetype with zero modern clinical evidence base for healthy adults — entirely a bodybuilding \"show prep hardening\" compound used in low-body-fat states for stage aesthetics. The historical 1961-1970s breast cancer indication (Drolban) is real but irrelevant to current use. No cognitive, athletic-performance, recovery, or longevity case for any healthy young adult. Same-family AAS skip-at-20 logic applies: HPG suppression during ongoing axis maturation (peak HPG at 20yo), atherogenic lipid changes (DHT-class HDL crash without E2 protection — non-aromatizing makes lipid profile worse on this dimension, not better), accelerated androgenic alopecia in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class), gray-market supply chain with high counterfeit rates. For this user (20yo MMA athlete, brain-priority, no contest-prep aesthetic goal), Masteron addresses no problem he has and produces no benefit he wants. Verdict reverses ONLY for older bodybuilder in active contest preparation with documented medical supervision — irrelevant to this user now or ever (combat sport ≠ bodybuilding aesthetics)."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, combat athlete with peak endogenous T (this user)
    SKIP-AT-

    Same-family AAS logic + the additional point that drostanolone is a purely cosmetic compound for stage aesthetics. Combat sport ≠ bodybuilding aesthetics; the "hardening" effect addresses no problem this user has. No cognitive benefit, no meaningful athletic performance benefit, no recovery benefit, real HPG suppression risk during axis maturation, accelerated hair loss in predisposed users, atherogenic lipid changes (worse on HDL than aromatizing AAS), gray-market supply chain with high counterfeit rates. Reconsider only post-30 if competitive bodybuilding ever becomes a goal — clinically implausible for this user.

  • 20-30 with documented severe catabolic indication
    N

    drostanolone has no FDA-approved catabolic indication; oxandrolone (FDA-approved for HIV wasting, severe burn) or testosterone replacement would be considered instead.

  • 30-50, executive maintenance with documented hypogonadism
    SKIP

    TRT (testosterone enanthate / cypionate) is the appropriate intervention, not Masteron. Drostanolone has no place in HRT protocols.

  • 30-50, bodybuilder in active contest preparation, with medical supervision
    OPTIONAL

    niche — the canonical use case for drostanolone. Run with test base, bloodwork monitoring, and recognition of HPG / lipid / hair / cardiac costs. Genuinely cosmetic; no health upside; only justifiable if competitive aesthetic is the explicit goal.

  • 50+, mild cognitive decline
    SKIP

    no indication; cardiovascular + lipid risk outweighs marginal cosmetic gains.

  • Anxiety-prone
    SKIP

    DHT-class CNS effects can drive irritability / aggression / mood lability in susceptible users.

  • High athletic load, tested status (NCAA, USADA, WADA, professional combat sport)
    SKIP-PERMANENT

    during testing window — S1.1 banned, weeks-to-months detection window via urine LC-MS/MS for both ester variants.

  • High athletic load, untested status (this user)
    SKIP

    as default. The risk profile (HPG suppression, atherogenic dyslipidemia, hair loss, gray-market supply) is independent of testing status. The compound provides no athletic performance benefit relevant to combat sport.

  • Sleep-disordered
    SKIP

    Address sleep first; drostanolone has no role and may modestly disturb sleep.

  • Recovery-focused (post-injury, post-illness, healthy young)
    SKIP

    for healthy young. BPC-157, TB-500 are far better-fit for injury recovery without HPG / lipid / hair costs.

  • Strength/anabolic-focused
    SKIP

    drostanolone is not a strength compound. If a strength-focused AAS conversation ever opens (it shouldn't at 20), testosterone enanthate is the more cost-effective and better-evidenced option, and even that is SKIP-AT-20.

  • Cosmetic / contest-prep focused
    T

    canonical use case. This is what the compound is for. Even here, it's a cosmetic specialty with health costs; not appropriate for casual aesthetics.

▸ Subjective experience (deep)

At bodybuilder doses (200-400 mg/week, 8-12 week run typically in contest prep)

  • Week 1-2: Subtle. Most users report "nothing happening yet" — consistent with the compound's modest absolute anabolic potency. Distinguishes Masteron from harsher cosmetic compounds (trenbolone) which produce immediate dramatic effects.
  • Week 2-4: First subjective signals — slightly fuller / harder muscle appearance under low body fat conditions; "tighter" feel; slight increase in vascularity at low body fat. Strength gains minimal. Libido often modestly elevated (DHT-class CNS effect + free-T elevation via SHBG displacement).
  • Week 4-8: Peak cosmetic effect — visible "hardening" in low-body-fat states (8% or below for men): more striated muscle bellies, more pronounced vascularity, reduced subcutaneous water (already low) appears further reduced. Mood typically neutral or mildly elevated; some users report mild aggression / drive elevation (DHT-class CNS effect). Libido often preserved or modestly elevated early-cycle, then degrades later as endogenous T suppresses without test base.
  • Week 8-12: Full aesthetic effect on stage / in mirror; bloodwork typically shows lipid degradation (HDL drop 30-50%), mild HPG suppression, mild transaminase elevation (less than orals).
  • Post-cycle: HPG recovery typically 4-8 weeks if cycle was short and PCT run; longer if Masteron run solo without test base (worse HPG outcome). Hair loss / acne progress in genetically predisposed users may be permanent.

Characteristic effects

  • "Dry / hard / vascular / striated" — the entire reason the compound is run
  • Minimal water retention (vs aromatizing AAS)
  • Modest libido shifts (initially up, later down)
  • Mild aggression / drive elevation in some users (DHT-class CNS)
  • Hair shedding / scalp thinning in genetically predisposed users (potent peripheral androgen, no 5α-reductase protection because already DHT-class — finasteride / dutasteride cannot mitigate)
  • Acne / oily skin in susceptible users (sebaceous gland AR activation)
  • No "fullness" or "pump" beyond what training + nutrition produces

What users do NOT report

  • Significant muscle gain (it's not that compound)
  • Significant strength gain
  • Cognitive enhancement
  • Recovery acceleration
  • Fat loss beyond what diet produces
  • The compound does not "do anything" if body fat is not already low — at 12%+ body fat, the cosmetic effect is invisible
▸ Tolerance + cycling deep dive
  • Tolerance buildup: AR receptor downregulation occurs with all AAS — not "tolerance" in CNS sense, but receptor saturation/downregulation creates diminishing returns past 8-12 weeks. Drostanolone-specific tolerance not well-characterized but follows standard AAS pattern.
  • Recommended cycle (bodybuilder convention): 8-12 weeks on, equal time off; rarely run >12 weeks because the cosmetic effect is contest-specific (run only when the user is at low body fat for show prep).
  • Reset protocol: Off-cycle 8-12 weeks minimum; PCT (clomid + nolva, or enclomiphene) typically starts 1-2 weeks post-cycle (propionate) or 2-3 weeks post-cycle (enanthate) and runs 4-6 weeks. HPG axis recovery generally faster than longer-acting injectables but slower than the "mild AAS doesn't suppress" myth implies.
▸ Stacking deep dive

Synergistic with (in bodybuilder protocols, NOT recommended for this user)

  • testosterone (cypionate / enanthate): Almost always run with test base; without it, mid-cycle hypogonadism symptoms (low libido, fatigue, mood drop) emerge. Test base is non-negotiable for any meaningful drostanolone cycle.
  • trenbolone: Synergistic for cutting / contest prep — drostanolone "hardens," trenbolone "shreds"; together produce the harshest cosmetic effect at the highest cardiovascular and neurological cost. Compound risks dramatically.
  • anavar (oxandrolone, oral): Sometimes added late-cycle for additional "dryness" — compounds DHT-class side effects (HDL crash, hair loss) without proportional benefit.
  • GH / IGF-1: Adds anabolic synergy; compounds cancer / cardiomyopathy / hypoglycemia risks.

Avoid stacking with

  • Other DHT-derivatives (primobolan / methenolone, winstrol, anavar / oxandrolone): Stacking multiple DHT-class compounds compounds androgenic side effects (hair, skin, prostate) and lipid impact without proportional muscle-building gain. Particularly bad for hair-loss-predisposed users.
  • Nandrolone / 19-nors: No direct contraindication but stacking creates pharmacological mess (different mechanism profiles, harder to attribute side effects); not commonly run together.
  • Aromatase inhibitors (anastrozole, letrozole): Drostanolone already non-aromatizing + mild anti-E2; AI on top crashes E2 too low → joint pain, mood issues, lipid worsening, libido collapse. Only consider AI if running aromatizing AAS (test) at high doses, in which case the AI dose may be slightly lower than monotherapy.
  • Finasteride / dutasteride (5α-reductase inhibitors): Ineffective for hair protection because drostanolone is already DHT-class (not a 5α-reductase substrate). The mechanism of finasteride / dutasteride does not apply; users with male-pattern baldness predisposition cannot mitigate drostanolone hair loss pharmacologically. (Finasteride remains useful for endogenous DHT modulation if the user has hair concerns from other AAS in stack, but does not protect from drostanolone itself.)
  • Equipoise / boldenone: No direct contraindication but mechanism-redundant for cutting goals; commonly stacked together in older bodybuilder protocols though less coherent than drostanolone monotherapy on test base.

Neutral / safe co-administration

  • Most non-hormonal nootropics (modafinil, citicoline, NAC, magnesium, fish oil — this user's V4 stack) — no direct interaction; the issue is not pharmacological collision but the underlying inappropriateness of cosmetic AAS use in a healthy young eugonadal male combat athlete.
▸ Drug interactions deep dive
  • Warfarin / anticoagulants: AAS class generally potentiates warfarin effect → dose reduction required, frequent INR monitoring.
  • Insulin and oral hypoglycemics: Modest insulin sensitivity changes possible; monitor glucose in diabetic patients (AAS class general).
  • CYP-mediated metabolism: Drostanolone is partially CYP3A4-metabolized; strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) may modestly elevate exposure, but no clinically significant interaction documented for drostanolone specifically.
  • Hepatotoxicity: Drostanolone enanthate and propionate (injectable, not 17α-alkylated) have minimal hepatotoxicity vs oral 17α-alkylated AAS. Mild transaminase elevation possible at high doses but typically reversible and modest.
  • Detection (WADA): S1.1 Anabolic Androgenic Steroids, banned in- and out-of-competition. Detection via urine LC-MS/MS for parent + metabolites; long-ester injectable means weeks-to-months detection window depending on dose / duration / individual metabolism. Propionate detection ~3-4 weeks; enanthate ~5-8 weeks. Irrelevant for this user's untested status, but relevant if combat-sport regulation tightens.
▸ Pharmacogenomics
  • AR (androgen receptor) CAG repeat length: Shorter CAG repeats = stronger AR signaling per unit ligand. Users with shorter repeats experience more pronounced androgenic side effects (hair loss, prostate, skin) at any given dose. Drostanolone is a potent peripheral androgen (DHT-class with 3α-HSD blocking) — for users with shorter CAG repeats and male-pattern baldness predisposition, this is one of the more aggressive AAS for hair loss specifically.
  • SRD5A2 (5α-reductase) variants: Mostly irrelevant for drostanolone since it's already DHT-class (not a 5α-reductase substrate). Variants matter for testosterone-class AAS metabolism, not drostanolone.
  • CYP3A4 polymorphisms: Modestly affect metabolism but no clinical pharmacogenomic dosing guidance exists.
  • Practical note: No pharmacogenomic test changes the SKIP-AT-20 verdict. Verdict is driven by indication / risk balance, not metabolic variability. The user's June 2026 23andMe may include AR CAG / SRD5A2 SNPs but interpretation will not change the SKIP recommendation.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx (US) None N/A N/A No FDA-approved indication. Drolban (drostanolone propionate) was FDA-withdrawn decades ago. No legitimate Rx pathway exists.
Gray-market UGL Common offerings on bodybuilding forums, telegram channels, dark markets $60-100 / 10mL @ 100-200mg/mL (propionate); $80-130 / 10mL @ 200mg/mL (enanthate) Low-to-medium — heavy counterfeit / underdosing Frequently underdosed or counterfeit (substituted with cheaper testosterone enanthate or boldenone, sold at Masteron prices). Independent lab testing (Anabolic Lab, Janoshik) flags meaningful counterfeit / underdosed rates. Enanthate ester less commonly produced than propionate by major UGLs — supply quality varies more for "Mast E" specifically.
Pharmaceutical-grade gray-market Limited international pharmacy availability for legitimate brand $200-400 / 10mL Medium Higher quality than UGL but still gray-market; legal exposure varies. Drostanolone propionate brands (Permastril, Metormon) survive in some non-US markets at limited availability.
Veterinary / research-chem Variable Variable Low Not a common path; drostanolone has no veterinary use case.

Counterfeit risk specifics

Drostanolone is one of the more frequently counterfeited AAS in the gray market. The compound is:

  1. More expensive than testosterone esters at pharmaceutical-grade and competent UGL level
  2. Less commonly verified than testosterone (fewer independent batches tested)
  3. Substitutable visually (clear oil; can be relabeled testosterone enanthate or boldenone undecylenate without obvious appearance differences)

Independent testing services (Anabolic Lab, Janoshik) regularly flag "Mast" labeled vials that contain testosterone enanthate, boldenone, or unidentified mixtures. Users who proceed despite the SKIP-AT-20 verdict should mandate batch-specific HPLC + mass-spec verification — for cosmetic use this matters because counterfeit "Mast" sold as test enanthate would aromatize, invalidating the entire reason for choosing drostanolone in the first place.

For this user

Sourcing is solvable but irrelevant — the compound is not appropriate for any goal a 20yo MMA athlete has. Skip the compound, do not engage the sourcing question.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Total + free testosterone, SHBG, LH, FSH, E2 (sensitive assay), DHT, prolactin, full lipid panel (LDL, HDL, total cholesterol, triglycerides, ApoB, ideally Lp(a)), ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin, CBC (hematocrit), HbA1c, fasting glucose, eGFR, blood pressure, PSA, semen analysis (if fertility-relevant), echocardiogram if multi-cycle intent, hair density photos (frontal hairline, temples, crown — baseline for tracking AAS-driven progression).
  • During use (week 4): ALT, AST, GGT, full lipid panel, blood pressure, hematocrit, hair photos. Flag if HDL drops >50%, BP >140/90, or visible hairline recession.
  • End of cycle: Full HPG panel (T, LH, FSH, E2, DHT) to quantify suppression; lipids; LFTs; hair photos for end-of-cycle baseline.
  • Post-cycle: HPG recovery check at week 4-8; full lipid recovery check at week 8-12; hair photos at 8-12 weeks (assess whether shedding has stabilized or progressed).
  • Long-term (multi-cycle users): Annual lipid trends, periodic echocardiogram, formal CVD risk recalculation, ongoing hair density photos as the most sensitive cosmetic-side-effect tracker.
▸ Controversies / open debates Live debate

1. Is drostanolone genuinely "anti-estrogen" or is the reputation overstated?

Claim: Drostanolone has anti-estrogen properties, can substitute for AI in stack, was used as breast cancer treatment. Reality: Real but limited. The historical breast cancer indication is real but was abandoned for tamoxifen because tamoxifen does the job better. The "anti-estrogen" effect in modern bodybuilding stacks is mild — it does not substitute cleanly for anastrozole / letrozole when running aromatizing AAS at high doses, and the mechanism (peripheral AR/ER cross-talk + minor aromatase substrate competition) does not block aromatization elsewhere. The reputation is folk-amplified.

2. Cosmetic-AAS framing — useful or pejorative?

The framing of drostanolone as "purely cosmetic" is technically accurate (the only documented modern use case is contest-prep aesthetics) but is sometimes contested in bodybuilding circles. Counter-claims:

  • "Drostanolone improves training-induced hardness even off-stage" — true at low body fat, invisible at higher body fat.
  • "Drostanolone is mild and good for first cycles" — false; it's a specialty compound with poor cost-benefit for general physique enhancement vs testosterone alone.
  • "Drostanolone has anti-aging / longevity uses" — no evidence.

The cosmetic framing accurately captures the use case. It does not pejoratively diminish bodybuilding as a discipline; it simply identifies the compound's actual scope.

3. Brain-development concerns at 20

Same-family AAS concern: AR signaling is active in CNS regions including hippocampus, amygdala, and prefrontal cortex; supraphysiologic AAS exposure during ongoing prefrontal maturation (continues into mid-20s) is largely unstudied for cognitive endpoints. Behavioral / mood literature on adolescent AAS use shows elevated rates of mood disorder and aggression but is confounded. Precautionary case favors skip, particularly given this user's brain-priority framing. Drostanolone-specific data is sparser than testosterone-class compounds but the AR-mediated mechanism is the same.

4. User-archetype specificity (combat sport vs bodybuilding)

Even within the AAS skip-at-20 cluster, drostanolone is particularly user-irrelevant for combat athletes:

  • Methenolone (Primobolan): at least nominally a "lean tissue" compound — could in theory be argued as a body-comp adder for an athletic profile (still skip at 20 same logic).
  • Oxandrolone (Anavar): has FDA indications (HIV wasting, severe burn) — at least a real clinical compound (still skip for healthy 20yo).
  • Testosterone: the foundational HRT compound — has legitimate endocrine medicine use case at any age with documented hypogonadism.
  • Drostanolone: no clinical indication, no athletic performance benefit, purely a cosmetic specialty for stage aesthetics — addresses zero problems a 20yo MMA athlete has.

For combat athletes specifically, "hardening" is not a goal. Combat sport rewards raw output (strength, speed, conditioning, recovery), brain-priority compounds (modafinil for film study, recovery sleep), and weight management (cutting weight with proper hydration / nutrition, not cosmetic vasculature). Drostanolone is structurally orthogonal to these goals.

5. Counterfeit market and safety implications

Drostanolone is one of the more frequently counterfeited AAS in independent lab testing. The cost differential between drostanolone (expensive to manufacture) and testosterone enanthate / boldenone (cheap) creates strong economic incentive for substitution. Users who think they're running drostanolone may actually be running 200 mg/week of testosterone enanthate or boldenone — both of which aromatize, invalidating the entire pharmacological rationale for choosing drostanolone (no aromatization, no E2 management). The counterfeit problem is not just a "wasted money" issue; it changes the actual pharmacological profile experienced. This adds a layer of harm to recreational use that is rarely discussed in bodybuilding forums.

6. Propionate vs enanthate — does ester choice matter?

Bodybuilding folklore sometimes claims drostanolone propionate "hits harder" or "feels different" than enanthate. Reality: pharmacodynamics are identical; only kinetics differ. Propionate's pulsatile profile (peak-trough variation across the EOD interval) may produce a more subjectively "felt" cycle, but the AR signaling, SHBG displacement, and downstream effects are the same. Enanthate's smoother profile is generally preferred for blood-test consistency in monitored cycles; propionate is preferred for harm reduction (faster mid-cycle abort if side effects emerge).

▸ Verdict change log
  • 2026-05-04 (Encyclopedia v5) — SKIP-AT-20, listed in AAS skip-at-20 family.
  • 2026-05-06 (masteron-enanthate.md) — SKIP-AT-20 MEDIUM confidence; ester-specific deep research on enanthate variant.
  • 2026-05-10 (this file, parent compound) — SKIP-AT-20 MEDIUM confidence. Affirmed and synthesized across both ester variants. Mechanism + evidence + cosmetic-AAS framing + user-archetype-specificity + counterfeit-market reality all reviewed; no plausible benefit case for healthy 20yo combat athlete with peak endogenous testosterone. Same-family AAS risks (HPG suppression, atherogenic dyslipidemia worsened by non-aromatization, hair loss in predisposed users without 5α-reductase rescue, gray-market supply with high counterfeit rates) plus the additional point that drostanolone addresses a problem (stage aesthetics) this user does not and will not have. Verdict reverses ONLY for older bodybuilder in active contest preparation with medical supervision — clinically implausible for this user now or ever (combat sport ≠ bodybuilding).
▸ Open questions / gaps Open
  • Long-term cardiovascular outcomes in healthy young adults using cyclic drostanolone: No prospective cohort data; extrapolated from broader AAS literature (Baggish 2017).
  • Drostanolone-specific lipid impact magnitude: Sparser data than testosterone or oxandrolone; HDL crash is consistent with DHT-class but exact magnitude per dose less well-characterized in modern literature.
  • Brain-development effects of supraphysiologic AR activation in 20-25yo prefrontal maturation window: Largely unstudied across AAS class.
  • Mechanism of "anti-estrogen" effect: Not fully characterized; appears mild and limited; does not substitute for AI in modern protocols. Modern receptor-binding studies of drostanolone are sparse.
  • SHBG displacement quantification: Documented qualitatively (Saartok 1984) but not quantified as a function of dose / duration in modern human cohorts.
  • Propionate vs enanthate counterfeit rates: Both heavily counterfeited; enanthate possibly more so due to lower UGL production volume and fewer independent benchmark tests.
▸ Cross-references
  • masteron-enanthate — long-ester variant; pharmacodynamically identical; ester-specific kinetics and detection-window differences.
  • testosterone — foundational AAS / HRT compound; mandatory base for any drostanolone cycle; SKIP-AT-20 absent documented hypogonadism.
  • primobolan (methenolone) — DHT-derivative AAS, "lean tissue" reputation, 1-methylated; SKIP-AT-20 same-family logic.
  • anavar (oxandrolone) — 17α-alkylated DHT oral, "mild" reputation, FDA-approved for catabolic states; SKIP-AT-20 with HIGH confidence.
  • trenbolone — 19-nor, harsh cosmetic / strength compound; SKIP-AT-20 with strongest CNS-risk emphasis in family; common stack partner with drostanolone in contest prep.
  • equipoise / boldenone — long-ester aromatizable AAS sometimes stacked with drostanolone; mechanism-different.
  • anastrozole — aromatase inhibitor; potentially redundant with drostanolone's mild anti-E2 effect; not stacked when drostanolone is run with non-aromatizing other AAS.
  • finasteride / dutasteride — 5α-reductase inhibitors; ineffective for hair protection during drostanolone use because drostanolone is already DHT-class.

References

Saartok T, Dahlberg E, Gustafsson JA. (1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of binding to androgen receptors in skeletal muscle and prostate, as well as to sex hormone-binding globulin." *Endocrinology* 114(6):2100-2106. PMID: 6539197.

pubmed.ncbi.nlm.nih.gov · 1984

Foundational AR + SHBG binding study including DHT-derivatives.

View Study

Talley RW et al. (1973). "A dose-response evaluation of androgens in the treatment of metastatic breast cancer." *Cancer* 32(2):315-320. PMID: 4515870.

acsjournals.onlinelibrary.wiley.com · 1973

32:2%3C315::AID-CNCR2820320206%3E3.0.CO;2-Q) — Historical breast cancer trial data including drostanolone propionate.

View Study

Baggish AL, Weiner RB, Kanayama G, et al. (2017). "Cardiovascular toxicity of illicit anabolic-androgenic steroid use." *Circulation* 135(21):1991-2002. PMID: 28533317.

pubmed.ncbi.nlm.nih.gov · 2017

Cardiac MRI cohort establishing AAS-class CV risk profile.

View Study

Pope HG Jr, Wood RI, Rogol A, et al. (2014). "Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement." *Endocrine Reviews* 35(3):341-375. PMID: 24423981.

pubmed.ncbi.nlm.nih.gov · 2014

Comprehensive AAS adverse-effect review.

View Study

Hartgens F, Kuipers H. (2004). "Effects of androgenic-anabolic steroids in athletes." *Sports Medicine* 34(8):513-554. PMID: 15248788.

pubmed.ncbi.nlm.nih.gov · 2004

Class overview including drostanolone.

View Study

Rasmussen JJ, Selmer C, Østergren PB, et al. (2016). "Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study." *PLoS One* 11(8):e0161208. PMID: 27536957.

journals.plos.org · 2016

Persistent post-AAS hypogonadism documentation; the empirical anchor for SKIP-AT-20.

View Source

Drolban (drostanolone propionate) — Wikipedia historical entry

en.wikipedia.org

historical FDA pathway, breast cancer indication, withdrawal context.

View Source

Drostanolone — Wikipedia

en.wikipedia.org

pharmacology overview, ester variants, historical use.

View Source

Drostanolone (DrugBank DB00858)

go.drugbank.com

drug-database entry covering pharmacology, mechanism, ADME.

View Source

Anabolic Lab (anabolic.org)

anabolic.org

Independent UGL/pharma testing data on AAS counterfeit rates including drostanolone.

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…